Constitutive BTK activation is essential for proliferation of abnormal B-cells in several types of blood malignancies including chronic lymphocytic leukemia (CLL) [300,301], mantle cell lymphoma [302,303], and lymphoplasmacytic lymphoma [304]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.